RT Journal Article
SR Electronic
T1 Adherence to home-based videogame treatment for amblyopia in children and adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.25.20113126
DO 10.1101/2020.05.25.20113126
A1 Tina Y. Gao
A1 Joanna M. Black
A1 Raiju J. Babu
A1 William R. Bobier
A1 Arijit Chakraborty
A1 Shuan Dai
A1 Cindy X. Guo
A1 Robert F. Hess
A1 Michelle Jenkins
A1 Yannan Jiang
A1 Lisa S. Kearns
A1 Lionel Kowal
A1 Carly S. Y. Lam
A1 Peter C. K. Pang
A1 Varsha Parag
A1 Roberto Pieri
A1 Rajkumar Nallour Raveendren
A1 Jayshree South
A1 Sandra Elfride Staffieri
A1 Angela Wadham
A1 Natalie Walker
A1 Benjamin Thompson
A1 on behalf of the BRAVO study team
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.25.20113126.abstract
AB Objective Home-based videogame treatments are increasingly being used for various sensory conditions, including amblyopia (“lazy eye”), but adherence continues to limit success. To examine detailed behavioral patterns associated with home-based videogame treatment, we analyzed in detail the videogame adherence data from the Binocular treatment of amblyopia with videogames (BRAVO) clinical trial (ACTRN12613001004752).Methods Children (7-12 years), Teenagers (13-17 years) and Adults (≥18 years) with unilateral amblyopia were loaned iPod Touch devices with either an active treatment or placebo videogame and instructed to play for 1-2 hours/day for six weeks at home. Objectively-recorded adherence data from device software were used to analyze adherence patterns such as session length, daily distribution of gameplay, use of the pause function, and differences between age groups. Objectively-recorded adherence was also compared to subjectively-reported adherence from paper-based diaries.Results 105 of the 115 randomized participants completed six weeks of videogame training. Average adherence was 65% (SD 37%) of the minimum hours prescribed. Game training was generally performed in short sessions (mean 21.5, SD 11.2 minutes), mostly in the evening, with frequent pauses (median every 4.1 minutes, IQR 6.1). Children played in significantly shorter sessions and paused more frequently than older age groups (p<0.0001). Participants tended to over-report adherence in subjective diaries compared to objectively-recorded gameplay time.Conclusion Adherence to home-based videogame treatment was characterized by short sessions interspersed with frequent pauses, suggesting regular disengagement. This complicates dose-response calculations and may interfere with the effectiveness of treatments like binocular treatments for amblyopia, which require sustained visual stimulation.Clinical trial ID ACTRN12613001004752Competing Interest StatementAuthors Benjamin Thompson and Robert F. Hess are named inventors on two patents (US 12528934 and US 8006372 B2) related to the contrast-balancing binocular videogame treatment used in the BRAVO clinical trial. Robert F. Hess is a scientific advisor to Amblyotech, a company that licenses the patents. All other authors do not have conflicts of interest or competing financial interests.Clinical TrialACTRN12613001004752Funding StatementThe BRAVO clinical trial was supported by research project grants from the Health Research Council of New Zealand (reference 13/169) and the Hong Kong Health and Medical Research Fund (reference 11122991). The Centre for Eye Research Australia receives Operational Infrastructure Support from the Victorian Government. The funding bodies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The BRAVO clinical trial had ethical approval at all 5 study sites. Institutional ethical approval was obtained from the University of Auckland Human Participants Ethics Committee, the University of Waterloo Research Ethics Committee, the McGill University Health Centre, the Human Research and Ethics Committee of the Royal Victorian Eye and Ear Hospital, and the Human Subjects Ethics Subcommittee of the Hong Kong Polytechnic University. The trial adhered to the principles in the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe main visual outcomes of the optical treatment and videogame treatment phases of the BRAVO clinical trial are available in the following two publications: 1) Optical treatment phase outcomes: Gao, T.Y., et al., Optical treatment of amblyopia in older children and adults is essential prior to enrolment in a clinical trial. Ophthalmic Physiol Opt, 2018. 36(2): p. 129-143. 2) Videogame treatment outcomes: Gao, T.Y., et al., Effectiveness of a Binocular Video Game vs Placebo Video Game for Improving Visual Functions in Older Children, Teenagers and Adults with Amblyopia: A Randomized Clinical Trial. JAMA Ophthalmol, 2018. 136(2): p. 172-181. De-identified datasets may be supplied on reasonable request, following approval of the trial Steering Committee. Please contact the corresponding author Dr Tina Gao or Prof Benjamin Thompson.